Skip to main content
Premium Trial:

Request an Annual Quote

Digilab Marketing Axela Instruments

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Digilab will market Axela's instruments in the US under an agreement announced today.

The deal calls for Digilab to market new versions of Toronto-based Axela's proprietary flow-through technologies, the Ziplex system and the dotLab mX system.

The Ziplex system is for gene and protein expression analysis and uses porous array technology to "fully automate hybridization and binding, washing, imaging, and data analysis without operator intervention," the two companies said in a statement.

The dotLab mX platform uses diffractive optics technology and label-free sensing to perform real-time immunoassay directly in complex samples, they added.

According to Joe Griffin, president of Digilab, based in Holliston, Mass., the next step in many of its proteomic and genomic customers' research is the validation of biomarker panels.

"By partnering with Axela, we can offer complete solutions from discovery to routine analysis, across a broad range of multiplex requirement," he said in a statement. "As part of the rapidly growing biomarker segment, we see product and application synergies in academic and clinical research, pharmaceutical discovery, and diagnostic development laboratories."

Financial and other terms of the deal were not disclosed.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.